The DEA seeks to raise 2027 research quotas to 33,296 grams of MDMA and 12,002 grams of ibogaine, drastically up from 2026 levels. Read more here.
Investing.com -- Compass Pathways Plc (NASDAQ:CMPS) shares rose 4.5% on Monday after the company completed its New Drug Application submission to the FDA for COMP360 psilocybin to treat treatment-resistant depression.
LONDON & JERSEY CITY, N.J., November 04, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel 2026 Healthcare Conference on November 11, 2026 and will participate in a fireside chat at 8:40am ET.
COMPASS Pathways reported third quarter 2026 results with a net loss of US$9.83 million, compared with US$137.72 million in the same period a year earlier, and a lower basic loss per share from continuing operations. The firm is pairing this shrinking quarterly loss with ongoing work to complete its FDA submission for COMP360. This approach tightens the link between its cash burn, trial progress and the potential timing of a first commercial depression treatment. We will now look at how...
Compass Pathways (CMPS) stock rebounds after Q3 results calm launch fears over psilocybin compound COMP360 as Usona completes FDA filings first. Read more here.
LONDON & JERSEY CITY, N.J., November 02, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depression and Bipolar Support Alliance (DBSA), today released a new report summarizing findings from a national survey of people living with TRD (n=261) and caregivers (n=73) on the self-reported realities of living with a condition that can profoundly affect daily life, revealing t
Compass Pathways is on the cusp of FDA approval for a proprietary version of psilocybin — the active drug in magic mushrooms.
Compass Pathways (NASDAQ:CMPS) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
LONDON & NEW YORK, October 02, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and re
COMPASS Pathways (CMPS) is back in focus after recent share price swings, with the mental health biotech drawing attention as investors reassess its psilocybin-based COMP360 pipeline and current valuation. Recent trading tells a mixed story for COMPASS Pathways. The share price fell around 4% over the last day and is down about 10% over the past week, yet the year to date share price return is close to 90% and the 1 year total shareholder return is roughly 116%. That combination suggests...
LONDON & NEW YORK, September 30, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will overse
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling. Speaking at T
Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global
Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial launch for treatment-resistant depression in the first half of 2027. Speaking
This is the newest page. Registered accounts read further back.